Kornimate/medical-research-clean huggingface dataset:
shear-wave elastography of hip stabilizers in healthy individuals

Conditions: Shear-wave Elastography of Hip Stabilizers in Healthy Individuals

Summary: the aim of this study is to provide a scientific basis for shear-wave elastography measurements of hip stabilizing muscles on healthy individuals. to assess the inter- and intra-user validity, 12 healthy volunteers were recruited for ultrasonographic assessment by two experienced physiatrists.


Eligibility criteria:
inclusion criteria: * healthy individuals * age 18-30 years * volunteering for the study * absence of musculoskeletal pathologies involving pelvic, hip, and/or knee joints. exclusion criteria: * recent complaints of pelvic, hip, and/or knee pain. * previous history of trauma or surgery, including the lumbar, pelvic, hip, or knee region. * congenital or acquired pathologies of pelvis or lower extremity.
effect of a low-glycemic-load and milk-free diet on acne severity

Conditions: Acne Vulgaris

Summary: the objective of this study is to assess the effect of a low-glycemic-load and milk-free diet on acne severity. igf-1 and a phosphorylated product of the mtorc pathway (p70s6k) will be assessed in both groups to explore the mtorc signaling pathway, which is thought to be related to clinical improvement in previous studies.


Eligibility criteria:
inclusion criteria: * mild, moderate or severe acne (gags score 15-44) * age: 14-20 years old * presence of acne for at least 2 months exclusion criteria: * diabetes * polycystic ovary syndrome * use of hormonal contraceptives * previous use of oral retinoids * use of oral antibiotics or topical antibacterial or retinoid agents in the last 2 months * use of medications known to cause or exacerbate acne including lithium, oral or injected retinoids, some anticonvulsant drugs, medications containing iodides or bromides * drug or alcohol abuse. * active smokers * anticipated difficulty attending visits or fear of blood draws
evaluation of the effectiveness of a diagnostic kit in the etiological diagnosis of fevers of the traveler

Conditions: Fevers of the Traveler

Summary: annually about 10 to 15 million international travelers from europe visit tropical countries. returning from a journey, fever is the cardinal symptom of many infections. this is the second reason for consultation (23%) for return from a trip, after digestive disorders (42%). urgent evaluation must always be proposed. although that may be the manifestation of a benign disease, fever of return can also presage a rapidly progressive and lethal disease. in 50% of cases, patients return home, after treatment and disappearance of symptoms, though the microorganism responsible for the pathology is not able to be identified. the prescription of a series of systematic biological examinations in the form of a diagnostic kit has shown its relevance and its effectiveness in improving the etiological diagnosis of endocarditis and pericardites for optimal support. in this study we propose to assess the effectiveness of the systematic prescription of a diagnostic kit 'fever of the traveler' to all patients hospitalized with a fever after returning from a trip. "ready to use" kit brings together in a single bag (i) instructions for use, (ii) the tubes, bottles and jars for the etiological diagnosis of fever of the traveler in the usual support (iii) an additional blood tube for research of pathogens emerging. primary: to assess the effectiveness of a diagnostic kit for the etiological diagnosis of fevers of travelers on the return. hypothesis: improvement of at least 15% of the etiological diagnosis of fevers of travelers on the return through the development of a diagnostic kit.


Eligibility criteria:
inclusion criteria: * patient with a t \>38.5 ° c with or without associated clinical signs. * patient who traveled outside metropolitan france within 45 days with the hospitalization. * patient is more than 18 years old. * patient who accept to have his medical records reviewed for research. * patient with health insurance exclusion criteria: * a feverish syndrome beyond 45 days after the return of their journey. * a clinical symptomatologie on the return to journey without associated fever, * minor(miner) ( 18 years). * pregnant or breast-feeding woman. * incapable major patient or outside state to express its consent.
efficacy of hydrogen breath test in the patients with irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: irritable bowel syndrome is characterized by abdominal discomfort and bowel habit change. it is increasing worldwide. but the pathophysiology of the irritable bowel syndrome is not proven. so, the treatment's target is the relief of the symptoms. small intestinal bacterial overgrowth considered as the cause of the irritable bowel syndrome. because, it is related to the postprandial abdominal discomfort and the abdominal discomfort could be relieved after taking antibiotics. there are several diagnostic methods for small intestinal bacterial overgrowth. hydrogen breath test is non-invasive method for diagnosis of the small intestinal bacterial overgrowth. but, there is no standardized cut-off value for the hydrogen breath test. so, we want to compare the hydrogen breath test between the irritable bowel syndrome patients and normal people. and then, we want to analyze the efficacy of hydrogen breath test for the diagnosis of irritable bowel syndrome.


Eligibility criteria:
inclusion criteria: 1. over 19 years old, male and female 2. normal people (control group, who has no abdominal symptoms - diarrhea, constipation etc.) 3. irritable bowel syndrome patients (irritable bowel syndrome means that within the last 3 months abdominal discomfort more than three days for a month and satisfies over the below two items) 1) symptom relived after defecation 2) bowel habit change, the times of defecation changed 3) the change of the morphology of the stool exclusion criteria: 1. patients who do not agree for participation 2. patients who have history for treatment of irritable bowel syndrome 3. patients who is uncontrolled diabetes mellitus 4. patients who have small bowel or large bowel diseases 5. patients who had surgery for abdomen 6. patients who are taking antibiotics, anti-depressants within 1 week 7. patients who are taking proton pump inhibitors or opioids for analgesics 8. patients who have history of bowel adhesion
validation of preference module of experience with allergic rhinitis nasal sprays questionnaire (earns-q)

Conditions: Rhinitis, Allergic, Perennial

Summary: the protocol section needs to be updated using the following text "the main goal of the study was to validate the preference module of the earns-q and to test the reliability using treatment satisfaction questionnaire for medicines (tsqm), a validated questionnaire for determining satisfaction among different treatment. the earns-q is divided into 2 modules, an experience module and a preference module. the experience module includes 28 items, fourteen attribute rating items followed by fourteen importance weighing questions. the preference module includes the same items along with preference questions related to each item as well as a global preference question.


Eligibility criteria:
inclusion criteria: * seasonal allergic rhinitis. * nasal allergy symptoms during the spring allergy season. exclusion criteria: * prior use of beclomethasone dipropionate or flunisolide. * significant concomitant medical conditions. * use of corticosteroids. * use of allergy and other identified medications during the study. * current tobacco use or tobacco use within the past year.

Keywords: questionnaire nasal spray seasonal allergic rhinitis nasal spray questionnaire allergic rhinitis
study of jdq443 in comparison with docetaxel in participants with locally advanced or metastatic kras g12c mutant non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: this is a phase iii randomized open label study designed to compare jdq443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (nsclc) harboring a kras g12c mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.

the study has been designed as a phase iii trial and consists of 2 parts: * randomized part will evaluate the efficacy and safety of jdq443 as monotherapy in comparison with docetaxel. participants randomized to docetaxel arm will have the opportunity to cross-over to jdq443 at disease progression per recist 1.1 confirmed by birc. * extension part will be open after final progression-free survival (pfs) analysis (if the primary endpoint has met statistical significance) to allow participants randomized to docetaxel treatment to crossover to receive jdq443 treatment regardless of progression on docetaxel. the study population will include adult participants with locally advanced or metastatic (stage iiib/iiic or iv) kras g12c mutant non-small cell lung cancer (by tissue or plasma as determined by a novartis-designated central laboratory or accepted local tests) who have received prior platinum-based chemotherapy and prior immune checkpoint inhibitor therapy administered either in sequence or as combination therapy. approximately 360 participants will be randomized to jdq443 or docetaxel in a 1:1 ratio stratified by prior line of therapy and ecog performance status.

Eligibility criteria:
inclusion criteria: * participant has histologically confirmed locally advanced/metastatic (stage iiib/iiic or iv) * participant has a kras g12c mutation present in tumor tissue or plasma prior to enrollment, as determined by a novartis designated central laboratory or by accepted local tests. * participants has received one prior platinum-based chemotherapy regimen and one prior immune checkpoint inhibitor therapy for locally advanced or metastatic disease * participant has at least 1 evaluable (measurable or non-measurable) lesion by recist 1.1 at the screening visit. exclusion criteria: * participants who have previously received docetaxel (except if received in neoadjuvant or adjuvant setting with no progression within 12 months after the of end of treatment), or any other kras g12c inhibitor. * participant has egfr-sensitizing mutation and/or alk rearrangement by local laboratory testing. participants with other druggable alterations will be excluded if required by local guidelines. * participant has known active central nervous system (cns) metastases and/or carcinomatous meningitis * participant has an history of interstitial lung disease or pneumonitis grade \> 1. other inclusion/exclusion criteria may apply

Keywords: nsclc non small cell lung cancer lung cancer cancer of the lung cancer of lung pulmonary cancer neoplasms, lung neoplasms, pulmonary
pilot study to validate ex vivo expression of specific biomarkers of human resolutive macrophages

Conditions: Inflammation

Summary: human resolutive macrophages are essential immune cells in the resolution of inflammation. this particular type of macrophages remains poorly known and currently there are no biomarkers to identify them in vivo. within umr1098-right, specific biomarkers (secreted molecules and membrane receptors) of human resolutive macrophages (healthy volunteers) have been identified in vitro, but their existence in vivo remains an outstanding issue. an exploratory study (lack of data from the literature) will validate the ex vivo expression of these markers in samples of patients whose inflammation is not, or little, supported by the available therapies (nsaids, biotherapies, corticosteroids).


Eligibility criteria:
inclusion criteria: * age limits (18-80 years) * information and non-opposition for participating in the study * patients suffering from periodontitis grade iii ou iv * patients suffering from microcristalline arthritis * patient with health insurance exclusion criteria: * patient under corticotherapy * pregnancy * non-compliant patient * patient with no health insurance * patient in exclusion period from an other study * legal incapacity

Keywords: macrophage inflammation inflammation resolution
effect of btl-899 device for non-invasive lipolysis on human upper arms

Conditions: Fat Burn

Summary: this study will evaluate the clinical safety and the performance of the btl-899 device during the treatment of upper arms.

the aim of the study is to confirm the efficacy and the safety of the treatment. the efficacy (reduction of excess adipose tissue) will be assessed via correct identification of pre-treatment and 3-months follow-up images by at least two out of three independent blinded evaluators. the fat reduction will be also measured by means of ultrasound. comfort and satisfaction will be assessed via standard questionnaires. safety measures will include documentation of adverse events (ae) during and after the procedures.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) of 20 to 35 kg/m2. * visible excess of adipose tissue at the treatment site * subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring and/or weight loss during study participation. * no procedure for fat reduction in the area in the last six months. * subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without effecting a significant change of weight in either direction during the study participation. exclusion criteria: * electronic implants (such as cardiac pacemakers, defibrillators, and neurostimulators) * cardiovascular diseases * vascular diseases (such as chronic venous insufficiency, deep venous thrombosis, varicose veins, etc.) * disturbance of temperature or pain perception * pulmonary insufficiency * metal implants * drug pumps * malignant tumor * hemorrhagic conditions * septic conditions and empyema * acute inflammations * systemic or local infection such as osteomyelitis and tuberculosis * contagious skin disease * elevated body temperature * pregnancy * breastfeeding * injured or otherwise impaired muscles in the arms * scars, open lesions, and wounds at the treatment area * basedow's disease * previous liposuction in the treatment area in the last six months * any other disease or condition at the investigator's discretion, e.g. dislocated shoulder or carpal tunnel syndrome than can pose danger to the patient or compromise the study
effect of hinex jelly on nutritional status in people with possible sarcopenia or sarcopenia

Conditions: Sarcopenia

Summary: hinex jelly is a jelly high protein supplement. this report is to investigate whether jelly high protein supplement can achieve greater muscle mass, muscle strength, physical performance and nutritional status in sarcopenia or possible sarcopenia subjects. it is 20 weeks randomized, crossover, self-controlled trials. the screening, recruitment and trial period were carried out from feb, 2022 to mar, 2023. patients were randomized to either a self-controlled phase,which intake 400\~500 kcal breakfast, or a supplement phase consume one servings of jelly high protein supplement (303 kcal, 15 g protein and 2400 mg bcaa per serving) and 100\~200 kcal food at breakfast per day, for 8 weeks. after a 4-week washout they cross over to the alternate treatment. the anthropometric measurements, sarcopenia parameters, nutritional assessment and hematology assessment data were measured at the week 0,8,12,20 and 24-hour dietary record were recorded at week 1,8,13,20.

parameters of sarcopenia, including the muscle mass assessment, handgrip strength and physical performance assessment.muscle mass and body composition were measured by bioelectrical impedance analysis (bia). a hand dynamometer was used to measure handgrip strength. physical performance was measured by short physical performance battery (sppb), 6-meter gait speed and 5-time chair stand test. mini nutritional assessment (mna) used to measure nutritional status. the hematology assessment including total protein, albumin, pre-albumin, transferrin, c-reactive protein (crp), vitamin d, calcium, glucose, insulin, homeostasis model assessment-estimated insulin resistance (homa-ir), total cholesterol, triacylglycerol, creatinine, creatine-kinase, alkaline phosphatase, glutamic oxaloacetic transaminase (got), glutamic pyruvic transaminase (gpt) and complete blood count.

Eligibility criteria:
inclusion criteria: * 40-85 years old, middle-aged and elderly subjects with possible sarcopenia or sarcopenia. according to awgs 2019, possible sarcopenia is defined as (1) handgrip strength \< 28 kg in men and \< 18 kg in women or (2) 5-time chair stand test ≥ 12 seconds; sarcopenia is defined as meet (1) or (2) plus appendicular skeletal muscle mass index (asmi) \< 7.0 kg/m2 in men and \< 5.7 kg/m2 in women. exclusion criteria: * bmi\>35 kg/m2, taking any special diet (i.e. vegan), be allergic to ingredient (i.e. milk or soy bean) and any seriously acute or chronic lung, liver, kidney, gastrointestinal, cancers diseases history.
adolescent idiopathic scoliosis and body schema

Conditions: Adolescent Idiopathic Scoliosis; Body Schema

Summary: adolescent idiopathic scoliosis is the most common form of scoliosis. although an increasing number of studies suggest that an abnormal sensory-motor integration critically contributes to the cause of adolescent idiopathic scoliosis , there is uncertainty about the level of the central nervous system explaining this dysfunction. therefore, the planned master's thesis study aims to compare proprioception, tactile acuity, right-left reasoning ability, motor imagery ability, including the evaluation of body schema, which is a sensorimotor representation in adolescent idiopathic scoliosis patients with healthy individuals. in addition, the relationship of these markers with posture results, body perception and quality of life of individuals with adolescent idiopathic scoliosis will be investigated as a secondary aim.


Eligibility criteria:
inclusion criteria (adolescent idiopathic scoliosis) * diagnosis of adolescent idiopathic scoliosis * age ⩾19 years old * curve severity over 10° exclusion criteria (adolescent idiopathic scoliosis) * history of spine surgery * surgery or trauma * secondary scoliosis * unable to fill out the questionnaires or attend the physical examination, * history of musculoskeletal injury in the last six months * known systematic and psychological illness * use of prescription medication inclusion criteria (adolescent healthy/untreated population) -age ⩾ 19 years matched for age/height/weight (+/-5 years; +/- 10 lbs; +/- 10cm) to a scoliosis participant exclusion criteria (adolescent healthy/untreated population) * history of spine surgery * spine deformity * surgery or trauma * primer and secondary scoliosis * unable to fill out the questionnaires or attend the physical examination, * history of musculoskeletal injury in the last six months * known systematic and psychological illness * use of prescription medication
influence of a inhaled corticosteroid therapy versus corticosteroid + laba therapy on the feno of asthmatic children

Conditions: Allergic Asthma

Summary: the purpose of the study is to investigate, whether the feno concentration of asthmatic children is influenced differently by inhaled corticosteroid compared to inhaled corticosteroid + long acting beta agonist. the study hypothesis is that the feno concentration is more decreased in patients with a combination therapy compared to those with a corticosteroid mono therapy.


Eligibility criteria:
inclusion criteria: * allergic asthma since \> 6 months equal or lower corticosteroid therapy before study entry fev1\>50% exclusion criteria: * severe asthma respiratory infection within the last 4 weeks smoking
gingival crevicular fluid and placental tissue levels of interleukin-17 as a possible marker for preterm labor in patients with chronic periodontitis

Conditions: Chronic Periodontitis; Preterm Labor

Summary: this case control-study measures the levels of interleukin-17 in gingival crevicular fluid and placental tissue samples of pregnant females as a possible marker in determining whether or not an association exists between chronic periodontitis and preterm labor. interleukin-17 is a pro-inflammatory cytokine whose levels have been proven to increase in periodontal disease.


Eligibility criteria:
inclusion criteria: 1. within the age range of 18-35 years 2. free of any systemic diseases as referenced from burket's oral medicine health history questionnaire (glick2008) 3. spontaneous normal term birth at ≥37 weeks of gestation without any obstetrical or medical complications 4. spontaneous preterm birth (ptb) at \<37 weeks of gestation after uterine contraction or rupture of membranes (keelan1999) exclusion criteria: 1. history of medications that may affect the study outcome, such as: current use of systemic corticosteroids or antibiotics for at least one month 2. genital and urinary tract infections 3. existing hypertension and diabetes mellitus before pregnancy, autoimmune disease, asthma, and chronic renal disease 4. multiple pregnancies, cervical cerculage, abnormal placentation, past history of preterm delivery, or antepartum hemorrhage 5. low or high maternal body mass index

Keywords: chronic periodontitis preterm labor preterm birth interleukin-17 il-17 periodontal disease periodontitis periodontal risk factors medical risk factors